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HPA-1a-negative platelet products are not routinely available for new-
borns with alloimmune thrombocytopenia. In this article we describe
a program established to identify normal pheresis donors who are
HPA-1a-negative and to organize their future donations so that our
regional blood center would always have an HPA-1a-negative platelet
product available. The solid phase red cell adherence assay was used
for initial screening of platelet pheresis products. HPA-1a-negative
donors were confirmed with the platelet suspension immunofluores-
cence test using three anti-HPA-1a sera. Screening of 2600 platelet-
pheresis donor samples identified 40 HPA-1a-negative donors. Of
these, 36 are active and are coded for recognition on the daily phere-
sis inventory sheet. Theoretically, assuming four donations per year
and donors’ cooperation with scheduling, these 36 donors would
enable us to have at least one HPA-1a-negative product available every
day.  In addition, a decision tree for patient management using plate-
let serology and availability of HPA-1a-negative products was devel-
oped. The GTI-PAK™12 is the major technique used for serologic
screening of mothers of patients thought to have neonatal alloim-
mune thrombocytopenia. By screening pheresis donors and develop-
ing a clinical decision tree, HPA-1a-negative products, a rare resource,
can be fully utilized. Immunohematology 1999;15:71–74.
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Approximately 2 percent of the population is nega-
tive for the HPA-1a antigen, i.e., HPA-1b homozygotes.
Neonatal alloimmune thrombocytopenia (NAIT) occurs
in 1 in 2000 to 1 in 5000 births with the platelet-specif-
ic antibody, anti-HPA-1a, being its most common cause.
NAIT is similar to hemolytic disease of the newborn
(HDN) in that maternal antibody crosses the placenta,
causing immune destruction of incompatible fetal
platelets. However, HDN does not usually occur in the
first pregnancy, whereas severe NAIT can occur in the
first pregnancy and may occur as early as 20 weeks ges-
tation.1,2 Thus, thrombocytopenia in such a newborn
may be a medical emergency. Ideally, HPA-1a-negative
platelet products should be continuously available.
Maternal platelet pheresis to provide HPA-1a-negative
platelets is a method for obtaining compatible platelets
for the neonate. However, in many cases, this is not pos-
sible for medical and logistical reasons. The mother may
have had a complicated delivery or be in a remote hos-
pital. Either circumstance could make pheresis difficult
or impossible. In addition, many hospitals are not
equipped to wash the platelets or to reduce the plasma
volume to remove maternal antibody that could further
affect the neonate.
HPA-1a-negative platelet products also have been pro-
vided from mothers of previously affected infants. These
women are generally not pheresis donors and, therefore,
have to be recruited when a patient is identified. This
results in a delay of several days before a product
becomes available. Furthermore, in our experience, the
antibody in these women remains in their serum for
many years. Therefore, it is preferable that these prod-
ucts be washed or at least volume reduced. A continu-
ing inventory of HPA-1a-negative pheresis platelets
would be a valuable resource. This article describes the
establishment of such a resource and the development
of an algorithm for its use.
Materials and Methods
Platelet preparation
Platelets for serologic testing are separated from EDTA
blood by centrifugation at 1000 RPM for 10 minutes. The
platelet-rich plasma is removed from the red blood cells
(RBCs) and centrifuged to obtain a platelet button. The
plasma is removed and the platelets are washed × 3 with
2.0 mL of phosphate-buffered saline (PBS)/EDTA. After
the final wash, the platelets are suspended in modified
Hanks Balanced Salt Solution for testing.
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Solid phase red cell adherence (SPRCA) assay
The SPRCA assay (Capture-P, Immucor, Inc., Norcross,
GA) was performed as previously described by Rachel et
al.3 Briefly, serum and a low-ionic-saline solution
(Immucor, Inc.) are added to a monolayer of platelets
that have been immobilized in microplate wells. The
microplates are incubated and washed with 200 μL of
PBS. Anti-human globulin (AHG)-coated RBCs (Immucor,
Inc.) are added to the wells and the microplates are cen-
trifuged.Negative results appear as tight buttons, where-
as positive results show diffuse adherence of coated
RBCs to the platelet monolayer.
Platelet suspension immunofluorescence test (PSIFT) 
The PSIFT described by von dem Borne et al.4 was
used. Serum and platelets are incubated for 30 minutes
in microplate wells and then washed × 3 with 200 μL
PBS/bovine serum albumin (PBS/BSA). A fluorescein-
tagged AHG(Cappel, Inc., Aurora, OH) is added to the
platelets, which are incubated in the dark at room tem-
perature for 30 minutes. The microplates are washed
again with PBS/BSA and 1 drop of glycerol/PBS is added.
Slides are prepared for microscopic examination of the
platelets. Visible membrane florescence indicates
platelet-reactive antibody.
GTI-PAK™12 assay
The GTI-PAK™12 is an enzyme-linked immunoadsor-
bent assay (ELISA; GTI, Brookfield,WI) in which diluted
serum is added to microwell strips and incubated at
37°C.5 The microwell strips are coated with platelet gly-
coproteins (GP) IIb/IIIa and Ia/IIa, affinity-purified HLA-
class I antigens, and GP Ib/Ix. Unbound immunoglobu-
lins are washed away with 200 μL GTI wash solution,
and an alkaline phosphatase-labeled AHG is added to the
trays and incubated at 37°C. The unbound AHG is
washed away with 200 μL GTI wash solution and the
enzyme substrate p-nitroptenyl phosphate is added to
the wells and incubated at room temperature in the
dark.The reaction is then stopped with sodium hydrox-
ide (NaOH) and the optical density (OD) of the color
produced is measured in a Dynatech micro ELISA reader
(Dynatech Inc.,Atlanta, GA). All reagents for the test are
provided in the kit.
Monoclonal antibody immobilization of platelet anti-
gens (MAIPA)  
The MAIPA assay was performed as previously
described by Kiefel et al.5 Briefly, platelets are incubat-
ed with a mouse monoclonal antibody (MOAB;
Immunotech, Inc., Westbrook, MA) to an individual GP
and serum. The platelets are lysed resulting in a triplex
of human antibody (if present), GP, and MOAB, which is
anchored to a microplate well with goat antimouse anti-
body (Jackson, Inc.,West Grove, PA). An enzyme-conju-
gated AHG (Jackson, Inc.) is added to the wells and incu-
bated. The unbound AHG is washed × 3 with TBS wash
buffer, which is prepared in our laboratory. An enzyme
substrate, paranitrophanyl phosphate tablets, obtained
from Sigma, Inc. (St. Louis, MO), is added and trays are
incubated again. The reaction is then stopped with
NaOH and the OD is measured in a Dynatech spec-
trophotometer.
Screening of pheresis products
Several times per week,platelets from 10 to 30 phere-
sis products are tested by SPRCA.3 The platelets from
those products found to be HPA-1a-negative are evaluat-
ed in confirmatory testing using PSIFT and three sources
of anti-HPA-1a. Approximately 85 percent of donors
identified by SPRCA are confirmed by PSIFT to be HPA-
1a-negative. Female donors who are found to be HPA-1a-
negative also are screened for HPA-1a antibody using
PSIFT. The donors confirmed as HPA-1a-negative in
PSIFT are asked to reschedule. On the subsequent dona-
tion, the platelets are retested using SPRCA and PSIFT.
Once reconfirmed as HPA-1a-negative, the donors are
entered into our computer database. Each time the
donors donate, the products are listed on the daily
pheresis inventory sheet with a code indication for HPA-
1a-negative status. Our pheresis recruitment department
tries to schedule at least two HPA-1a-negative donors
weekly. This results in HPA-1a single donor platelets
being available most of the time.
Testing of parents of newborns with suspected NAIT
Using SPRCA, maternal serum is crossmatched with
paternal platelets, and both maternal and paternal
platelets are typed for the HPA-1a antigen with appro-
priate controls. An antibody screen for platelet-reactive
antibody is performed on maternal serum using the GTI-
PAK™12. These results are available in less than 3 hours
and are used in the management protocol for the
neonate decision tree (Fig. 1).
These immediate tests indicate whether there is an
HPA-1 incompatibility between the mother and father
and whether the mother has HPA-1a antibody. In
approximately 10 percent of cases, the incompatibility is
present but antibody cannot be detected. If the clinical
situation is typical for NAIT, we treat such cases as HPA-
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1a alloimmunization. Further studies are done over the
next few days to completely define the situation.
Confirmatory HPA-1 testing is batched and performed
weekly by PSIFT. It includes direct testing of maternal
platelets for antibody bound to autologous platelets,anti-
gen typing, and confirmation of maternal antibody. In
cases where maternal platelets type as HPA-1a-negative,
paternal platelets are typed serologically for the HPA-1b
antigen to determine if the father is homozygous or het-
erozygous in the HPA-1a system. DNA testing at a refer-
ence laboratory is suggested for confirmation. Both par-
ents are typed for HPA-3a as well. In unusual
circumstances, such as a negative GTI-PAKTM12 assay
when the appropriate parental incompatibility is pre-
sent, the MAIPA assay also may be performed.
Protocol for Suspected NAIT
A platelet count of ≤ 20,000 μL or bleeding in the
neonate may be an indication for immediate transfusion.
Blood samples are referred to our laboratory for anti-
body identification and the current pheresis inventory is
reviewed for the availability of an HPA-1a-negative phere-
sis product (Fig. 1). If available, it is sent for transfusion.
If not, a randomly selected product is sent. In some
instances,a surprisingly good increment in the neonate’s
platelet count may be achieved with HPA-1a-positive
platelets.6 The reason for this is unknown. A possible
explanation is that the antigen-positive platelets may
overwhelm the antibody in the infant’s circulation.
Some neonatologists will administer intravenous gam-
maglobulin in addition to random donor platelets.7 In
each of these instances, an HPA-1a-negative donor is
recruited in case additional transfusions are needed and
HPA-1a antibody is identified.
When antibody testing has been completed,decisions
made are based on the results. If anti-HPA-1a antibody
and/or appropriate HPA-1 incompatibility has been iden-
tified,the above steps are followed. However,if anti-HPA-
1a antibody or HPA-1 incompatibility is not identified,no
further HPA-1a-negative platelets are issued and different
approaches are taken. If the maternal–paternal cross-
match and the GTI-PAK™12 are negative, the use of ran-
domly selected platelets is recommended. If other anti-
bodies are present, a crossmatch-compatible product
may be selected for transfusion. In this case, further
platelet serology studies and an HLA cytotoxic antibody
screen is needed. Most commonly, this reactivity will be
to HLA antigens but, more rarely, antibodies to platelet-
specific antigens may be present. If the antibody screen
is negative by GTI-PAK™12, a random donor platelet is
selected and further studies are performed to detect the
presence of antibodies to low-incidence platelet anti-
gens. In this case, the mother may be selected as a
donor, if eligible.
Results
The screening of 2600 pheresis products over 5 years
has identified 40 HPA-1a-negative donors (2%), of which
36 donate frequently. There were a total of 208 HPA-1a-
negative donations last year for an average of four prod-
ucts theoretically available each week. In an effort to
identify and obtain a greater number of HPA-1a-negative
products, pheresis donors continue to be screened reg-
ularly.
Our laboratory has evaluated 441 cases of suspected
NAIT. The summary of our finding is anti-HPA-1a was
identified in 91 cases, 144 cases contained no antibody,
129 cases had HLA antibody, and 77 contained other
platelet-specific antibodies.
Fig. 1. A decision tree using platelet serology and 
HPA-1a-negative products
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Case Report
A stat sample on a para 1, gravida 4 woman was
referred to our laboratory for a suspected case of NAIT.
In initial SPRCA testing, maternal serum was incompati-
ble with paternal platelets. Maternal platelets typed as
HPA-1a-negative;paternal platelets were HPA-1a-positive.
Simultaneously,serologic testing using GTI-PAK™12 was
performed. A definitive anti-HPA-1a was demonstrated
using this kit. Concurrent with testing, a review of the
inventory indicated an HPA-1a-negative pheresis product
was available. It was sent to the hospital and was on
standby for transfusion less than 12 hours after receipt
of the patient’s sample. Subsequently, results were con-
firmed by PSIFT and the paternal platelets were found to
be homozygous for the HPA-1a antigen. This case repre-
sents a stat situation in which serologic testing could be
performed prior to selection of products for transfusion.
Conclusion
The implementation of a transfusion protocol based
on our NAIT platelet selection decision tree has
improved our ability to provide an appropriate product
for transfusion in a timely manner. Our laboratory test-
ing protocol uses SPRCA for maternal and paternal HPA-
1a antigen typing and crossmatching of maternal serum
with paternal platelets. Antibody identification is accom-
plished using the GTI-PAK™12 assay. This enables us to
provide a definitive preliminary report in less than 3
hours from receipt of stat specimens because the Pak-12
is able to identify multiple antibodies. Continued screen-
ing of pheresis donors for the HPA-1a antigen has
increased the availability of HPA-1a-negative products for
transfusion. These factors, in addition to effective com-
munication with our customers, have enabled us to sup-
ply HPA-1a-negative or crossmatch-compatible products
for transfusion since January 1995.
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